Oncolytics Biotech (ONCY) Competitors $0.74 -0.03 (-3.76%) (As of 05:44 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends ONCY vs. FULC, ACB, FATE, LXEO, DMAC, ZNTL, TNYA, ATAI, ACRS, and ACRVShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include Fulcrum Therapeutics (FULC), Aurora Cannabis (ACB), Fate Therapeutics (FATE), Lexeo Therapeutics (LXEO), DiaMedica Therapeutics (DMAC), Zentalis Pharmaceuticals (ZNTL), Tenaya Therapeutics (TNYA), Atai Life Sciences (ATAI), Aclaris Therapeutics (ACRS), and Acrivon Therapeutics (ACRV). These companies are all part of the "pharmaceutical products" industry. Oncolytics Biotech vs. Fulcrum Therapeutics Aurora Cannabis Fate Therapeutics Lexeo Therapeutics DiaMedica Therapeutics Zentalis Pharmaceuticals Tenaya Therapeutics Atai Life Sciences Aclaris Therapeutics Acrivon Therapeutics Fulcrum Therapeutics (NASDAQ:FULC) and Oncolytics Biotech (NASDAQ:ONCY) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, earnings, institutional ownership and community ranking. Does the MarketBeat Community believe in FULC or ONCY? Oncolytics Biotech received 58 more outperform votes than Fulcrum Therapeutics when rated by MarketBeat users. Likewise, 68.12% of users gave Oncolytics Biotech an outperform vote while only 61.25% of users gave Fulcrum Therapeutics an outperform vote. CompanyUnderperformOutperformFulcrum TherapeuticsOutperform Votes9861.25% Underperform Votes6238.75% Oncolytics BiotechOutperform Votes15668.12% Underperform Votes7331.88% Which has higher valuation and earnings, FULC or ONCY? Oncolytics Biotech has lower revenue, but higher earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Oncolytics Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFulcrum Therapeutics$80.87M2.93-$97.33M-$0.31-14.19Oncolytics BiotechN/AN/A-$20.56M-$0.27-2.86 Do analysts recommend FULC or ONCY? Fulcrum Therapeutics currently has a consensus price target of $9.33, indicating a potential upside of 112.12%. Oncolytics Biotech has a consensus price target of $4.00, indicating a potential upside of 418.81%. Given Oncolytics Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Oncolytics Biotech is more favorable than Fulcrum Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fulcrum Therapeutics 1 Sell rating(s) 6 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.20Oncolytics Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FULC or ONCY more profitable? Fulcrum Therapeutics' return on equity of -7.31% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Fulcrum TherapeuticsN/A -7.31% -6.74% Oncolytics Biotech N/A -141.15%-84.73% Does the media refer more to FULC or ONCY? In the previous week, Fulcrum Therapeutics had 2 more articles in the media than Oncolytics Biotech. MarketBeat recorded 5 mentions for Fulcrum Therapeutics and 3 mentions for Oncolytics Biotech. Oncolytics Biotech's average media sentiment score of 0.85 beat Fulcrum Therapeutics' score of 0.80 indicating that Oncolytics Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fulcrum Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oncolytics Biotech 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders hold more shares of FULC or ONCY? 89.8% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 6.8% of Oncolytics Biotech shares are owned by institutional investors. 4.1% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 0.1% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has more volatility & risk, FULC or ONCY? Fulcrum Therapeutics has a beta of 2.14, suggesting that its share price is 114% more volatile than the S&P 500. Comparatively, Oncolytics Biotech has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. SummaryFulcrum Therapeutics and Oncolytics Biotech tied by winning 8 of the 16 factors compared between the two stocks. Ad Behind the MarketsWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Click to get the name and ticker symbol Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ONCY vs. The Competition Export to ExcelMetricOncolytics BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$59.42M$6.85B$5.15B$9.28BDividend YieldN/A3.06%4.81%4.06%P/E Ratio-2.8610.79135.4217.51Price / SalesN/A286.571,184.62142.21Price / CashN/A56.6540.4237.95Price / Book2.865.404.894.94Net Income-$20.56M$152.04M$118.71M$225.59M7 Day Performance-9.69%-4.19%15.74%-1.07%1 Month Performance-22.51%2.70%15.70%7.23%1 Year Performance-39.29%17.16%34.85%22.97% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCYOncolytics Biotech2.5369 of 5 stars$0.74-3.8%$4.00+439.1%-42.9%$57.19MN/A-2.7530News CoverageHigh Trading VolumeFULCFulcrum Therapeutics2.2285 of 5 stars$4.42+11.6%$9.33+111.2%-15.8%$238.41M$80.87M-13.68100Positive NewsACBAurora Cannabis0.3153 of 5 stars$4.30-0.2%N/A-6.9%$235.81M$200.35M-5.671,073FATEFate Therapeutics3.6944 of 5 stars$2.05+12.0%$6.75+229.3%-37.7%$233.48M$13.45M-1.22550Short Interest ↑LXEOLexeo Therapeutics3.0201 of 5 stars$6.99+1.6%$23.80+240.5%-44.4%$231.13M$650,000.00-2.1858Positive NewsDMACDiaMedica Therapeutics3.0067 of 5 stars$5.37-0.2%$7.00+30.4%+89.1%$229.62MN/A-9.6120Short Interest ↓News CoveragePositive NewsZNTLZentalis Pharmaceuticals2.5686 of 5 stars$3.22+4.2%$10.00+210.6%-78.7%$229.46MN/A-1.24160TNYATenaya Therapeutics3.9642 of 5 stars$2.85+3.6%$17.33+508.2%-32.2%$225.78MN/A-1.91110Analyst ForecastNews CoverageATAIAtai Life Sciences2.9734 of 5 stars$1.34-1.5%$9.00+571.6%+4.8%$224.86M$331,000.00-1.6883Positive NewsACRSAclaris Therapeutics3.7152 of 5 stars$3.06-5.0%$8.80+187.6%+222.8%$218.58M$31.25M-6.1986ACRVAcrivon Therapeutics1.2653 of 5 stars$7.02-0.6%$23.67+237.1%+57.1%$218.58MN/A-2.6158Gap Down Related Companies and Tools Related Companies Fulcrum Therapeutics Competitors Aurora Cannabis Competitors Fate Therapeutics Competitors Lexeo Therapeutics Competitors DiaMedica Therapeutics Competitors Zentalis Pharmaceuticals Competitors Tenaya Therapeutics Competitors Atai Life Sciences Competitors Aclaris Therapeutics Competitors Acrivon Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ONCY) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ONCY Stock Alerts